Michelle Rudek
Overview
Explore the profile of Michelle Rudek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hill K, Abbott N, Na J, Rudek M, Moore K, Lee E, et al.
J Pharm Biomed Anal
. 2024 Oct;
253():116531.
PMID: 39454543
An isotope-dilution bioanalytical assay for abemaciclib and its metabolites in combination with olaparib was developed and validated in human plasma K2 EDTA. For the quantitative assay, human plasma samples (or...
2.
Ahluwalia M, Ozair A, Rudek M, Ye X, Holdhoff M, Lieberman F, et al.
Cell Rep Med
. 2024 Jul;
5(7):101630.
PMID: 38955178
Recurrent high-grade gliomas (rHGGs) have a dismal prognosis, where the maximum tolerated dose (MTD) of IV terameprocol (5 days/month), a transcriptional inhibitor of specificity protein 1 (Sp1)-regulated proteins, is 1,700 ...
3.
Lee E, Coulter J, Mishra A, Caramella-Pereira F, Demarzo A, Rudek M, et al.
Trials
. 2023 Dec;
24(1):809.
PMID: 38104131
Background: Prostate cancer remains the most prevalent malignancy and the second-leading cause of cancer-related death in men in the USA. Radiation therapy, typically with androgen suppression, remains a mainstay in...
4.
Li M, Smith B, Jaeyeun L, Petr J, Wiseman R, Anders N, et al.
Res Sq
. 2023 Nov;
PMID: 37986957
Background: Antiviral therapies that target herpesviruses are clinically important. Nelfinavir is a protease inhibitor that targets the human immunodeficiency virus (HIV) infections aspartyl protease. Previous studies demonstrated that this drug...
5.
Haigentz M, Moore P, Bimali M, Cooley T, Sparano J, Rudek M, et al.
Oncologist
. 2022 Apr;
27(8):623-e624.
PMID: 35429391
Background: Persons living with human immunodeficiency virus are an underserved population for evidence-based cancer treatment. Paclitaxel and carboplatin (PCb) is an active regimen against a variety of solid tumors, including...
6.
Gerritse S, Janssen J, Labots M, de Vries R, Rudek M, Carducci M, et al.
Cancer Treat Rev
. 2021 Apr;
97:102171.
PMID: 33823432
Background: Innovative strategies to fully exploit the antitumor activity of multitargeted tyrosine kinase inhibitors (TKIs) are urgently needed. Higher concentrations of TKIs at their target site, i.e. intratumorally, may lead...
7.
Date A, Kates M, Yoshida T, Babu T, Afzal U, Kanvinde P, et al.
Drug Deliv Transl Res
. 2020 Nov;
11(5):2085-2095.
PMID: 33164163
Intravesical chemotherapy is a key approach for treating refractory non-muscle-invasive bladder cancer (NMIBC). However, the effectiveness of intravesical chemotherapy is limited by bladder tissue penetration and retention. Here, we describe...
8.
Chen Y, Li S, Lane A, Connolly C, Del Rio C, Valles B, et al.
Biol Blood Marrow Transplant
. 2014 Sep;
20(12):2042-8.
PMID: 25239228
The fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation is associated with a high relapse rate for patients with acute myeloid leukemia (AML) even after allogeneic hematopoietic stem cell...
9.
Ma H, Nguyen B, Li L, Greenblatt S, Williams A, Zhao M, et al.
Blood
. 2014 Jan;
123(10):1525-34.
PMID: 24408321
More than 35% of acute myeloid leukemia (AML) patients harbor a constitutively activating mutation in FMS-like tyrosine kinase-3 (FLT3). The most common type, internal tandem duplication (ITD), confers poor prognosis....
10.
Hammers H, Verheul H, Salumbides B, Sharma R, Rudek M, Jaspers J, et al.
Mol Cancer Ther
. 2010 May;
9(6):1525-35.
PMID: 20501804
Tyrosine kinase inhibitors (TKI) targeting angiogenesis via inhibition of the vascular endothelial growth factor pathway have changed the medical management of metastatic renal cell carcinoma. Although treatment with TKIs has...